Okogen, Inc. has received authorization from the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, to proceed with the EMERALD Phase 1/2 clinical trial of Treyegen (OKG-0303) for acute infectious conjunctivitis. The decision clears a critical regulatory hurdle for a therapy that could change how clinicians approach one of the most common eye infections, particularly in primary care and urgent care settings where rapid, broad-spectrum treatment is needed.
The EMERALD study will enroll more than 300 patients and is designed to evaluate safety, pharmacokinetics, virologic and microbiologic activity, and clinical efficacy. Data are expected later this year. That timeline matters: if the results confirm the drug's dual-action profile, Treyegen could become the first single investigational therapy to address both viral and bacterial forms of acute infectious conjunctivitis, reducing the diagnostic uncertainty that often forces clinicians to either prescribe antibiotics indiscriminately or wait for test results that may not be available in time.
Treyegen combines ranpirnase, a host-directed antiviral, tobramycin, a broad-spectrum antibacterial, and oxymetazoline, which reduces ocular redness, into one proprietary ophthalmic formulation. That design targets the broad clinical presentation of acute infectious conjunctivitis rather than a single pathogen. The practical implication is a potential shift away from the current trial-and-error approach, where viral cases may be treated with unnecessary antibiotics and bacterial cases may go undertreated. A single therapy capable of covering both could simplify treatment decisions, reduce antibiotic misuse, and offer patients faster symptom relief.
Beyond conjunctivitis, the CDSCO authorization serves as a validation of Okogen's broader host-directed antiviral platform built around ranpirnase. The company is advancing ranpirnase-based therapies across four pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. By positioning ophthalmology as the lead clinical proving ground, Okogen aims to generate clinical insights, formulation expertise, and manufacturing capabilities that can be applied across a wider portfolio of antiviral therapies. For investors and partners, the EMERALD study is therefore not just a single-asset trial but a test of whether the platform can deliver on its promise in a live clinical setting.
For more details, the full announcement is available via click here. Additional information about the company can be found at www.okogen.com.
The move also signals growing regulatory openness in India to innovative ophthalmic therapies, which could ease future trial recruitment and market entry if the data are positive. With enrollment exceeding 300 patients, the EMERALD study is large enough to generate meaningful safety and efficacy signals, yet early enough to allow rapid iteration on formulation or endpoint strategy. If successful, Treyegen could set a new standard for treating acute infectious conjunctivitis and provide a template for other host-directed antivirals targeting mucosal infections.
